UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Choroid Plexus Tumors
Pituitary Tumor
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Pineal Region Tumors
Glioma
Astrocytoma
Medulloblastoma
Oligodendroglioma
Glioblastoma
Ependymoma
Primary Objectives:
Conditions
Diffuse Midline Glioma
Conditions
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Glioma
Glioblastoma
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Natural killer (NK) cells are immune cells that recognize and get rid of abnormal cells in the body, including tumor cells and cells infected by viruses. NK cells have been shown to kill different types of cancer, including brain tumors in laboratory settings.
Conditions
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
The goal of this registry study is to collect more information to help identify clinical, biological, and imaging factors that can predict outcomes for ATRT.
Conditions
Glioma
The primary objective of the trial is to determine if there is a difference in rate of rebound and/or clinical progression necessitating the reinstitution of treatment at 4 months after stopping or weaning therapy with dabrafenib and trametinib in participants with newly diagnosed or recurrent/pr
Conditions
Ependymoma
There are very few treatment options for children and young adults whose posterior fossa Group A (PFA) ependymoma has come back or continued to grow after surgery and radiation.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Oligodendroglioma
This study will evaluate the feasibility and efficacy of various cognitive rehabilitation treatments in patients with grade II-III glioma.
Conditions
Meningioma
This phase II clinical trial will evaluate the safety and efficacy of stereotactic radiosurgery and pembrolizumab in treating patients with recurrent meningioma (grades I-III).
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This phase I study will evaluate the safety, dose-limiting toxicities, and preliminary efficacy of vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant glioma.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Subependymal giant cell astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I trial study will evaluate the dosage, safety and efficacy of trametinib and everolimus in treating pediatric and young adult patients with recurrent low-grade glioma.
Conditions
Glioma
Glioblastoma
This is a phase 1/2a study to assess the safety, dose-limiting toxicities, recommended Phase 2 schedule, and preliminary efficacy of aminolevulinic acid sonodynamic therapy in patients with recurrent or progressive GBM.
Conditions
Glioma
Glioblastoma
This is a phase 0/I exploratory study to evaluate the safety and toxicity profile of anti-TIGIT AB154 in combination with anti-PD-1 AB122 in patients with recurrent glioblastoma.